MedTrace Logo

BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)

NCT02834364 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2023-11-24

No results posted yet for this study

Summary

Trial for patients with refractory multiple myeloma after failure of at least two treatment regimens and with BRAFV600E/K Mutation to evaluate the efficacy of the kinase inhibitors Encorafenib (LGX818 in) combination with Binimetinib (MEK162).

Conditions

Interventions

DRUG

Encorafenib

450 mg p.o. once daily. One cycle is defined as 28 days

DRUG

Binimetinib

45 mg p.o. twice daily. One cycle is defined as 28 days

Sponsors & Collaborators

  • Array BioPharma

    collaborator INDUSTRY

  • German Cancer Research Center

    collaborator OTHER

  • Coordinating Centre for Clinical Trials Heidelberg

    collaborator UNKNOWN

  • University Hospital Heidelberg

    collaborator OTHER

  • University of Heidelberg Medical Center

    lead OTHER

Principal Investigators

  • Marc S. Raab, PD Dr. med. · Medizinische Klinik V, University Hospital Heidelberg

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2023-03-29
Completion
2023-03-29

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02834364 on ClinicalTrials.gov